Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast CancerClin. Cancer Res 2021 Oct 06;[EPub Ahead of Print], S Kuemmel, M Campone, D Loirat, RL Lopez, JT Beck, M De Laurentiis, SA Im, SB Kim, A Kwong, GG Steger, EZ Adelantado, FP Duhoux, R Greil, I Kuter, YS Lu, A Tibau, M Özgüroğlu, CW Scholz, CF Singer, E Vega, P Wimberger, C Zamagni, XM Couillebault, L Fan, N Guerreiro, J Mataraza, J Sand-Dejmek, A Chan
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.